CBX

 Alphamab Oncology has submitted the IND application for JSKN016, an anti-HER3xTROP2 ADC designed for the treatment of solid tumors in China. JSKN016 represents a potential first-in-class bispecific ADC, developed using the glycan-specific conjugation platform to target both HER3 and TROP2. No further details have been reported, and we will provide updates as they become available. Anti-TROP2 ADC, sacituzumab govitecan, has received approval for the treatment of breast cancer and urothelial cancer. Lung cancer may be the next targeting indication. Concurrently, anti-HER3 ADCs are widely investigated for their therapeutic potential in both lung cancer and breast cancer.

  CSPC and its subsidiary, Megalith Biopharma, have submitted the Investigational New Drug (IND) application for SYS6023, an anti-HER3 ADC, in China. SYS6023 In 2021, Megalith Biopharma filed a patent (WO2023088382) covering anti-HER2, anti-HER3, and anti-EGFR ADC, as well as the use thereof. Megalith made a notable change to the payload, opting for JSSW-001, which differs from Daiichi Sankyo's Patritumab deruxtecan (HER3-DXd). In experiments involving the Difi and SW620 colorectal cancer models, the Tumor Growth Inhibition (TGI) of Patritumab-JSSW-001 (DAR=7.36) exceeded that of the HER3 DXd. Anti-HER3 ADC in China SHR-A2009 Hengrui's anti-HER3 ADC, SHR-A2009, is currently in phase 1/2 trials, both as a monotherapy and in combination with Adebrelimab (anti-PD-L1 mAb) or Almonertinib (EGFRi) for non-small cell lung cancer (NSCLC). The first IND application for SHR-A2009 was submitted in August 2021. In October 2023, Hengrui reported the results of phase 1 trial: In evaluable NS